Search
Careers
Contact
About Us
About Sosei Heptares
Corporate Details
Mission, Vision, Values
Celebrating 30 Years
Our Leadership
Board of Directors
Executive Officers
Locations
Global Policies
Disclosure Policy
Social Media Policy
Privacy Notice
Cookie Policy
Laboratory Animal Care Policy
Whistleblowing Policy
Our Science
Our Science
What are GPCRs
Proprietary Research Platform
Intellectual Property
Scientific Advisory Board
Clinical Data and Presentations
Science Center - CHISHIKI
Other Programs for Partnering
Our Pipeline
R&D Pipeline
In-house Programs
Partnered Programs
Our Medicines
Ultibro® and Seebri®
Enerzair® Breezhaler®
ORAVI®
PIVLAZ®
Newsroom
Press releases
In the News
Publications
Investors
Financial & IR Information
Presentations and Webcasts
Financial Results
Securities Reports
Annual Report
Financial Highlights
Analyst Coverage
Analyst Report
Stock Information
General Stock Information
Shareholder's Meetings & Publications
Corporate Governance
ESG Report 2022
Corporate Governance Report
Corporate Governance Guidelines
Modern Slavery Statements
Other IR Information
IR Blog (Japanese Only)
Events
Email Alerts
Search
Careers
Contact
About Us
About Sosei Heptares
Corporate Details
Mission, Vision, Values
Celebrating 30 Years
Our Leadership
Board of Directors
Executive Officers
Locations
Global Policies
Disclosure Policy
Social Media Policy
Privacy Notice
Cookie Policy
Laboratory Animal Care Policy
Whistleblowing Policy
Our Science
Our Science
What are GPCRs
Proprietary Research Platform
Intellectual Property
Scientific Advisory Board
Clinical Data and Presentations
Science Center - CHISHIKI
Other Programs for Partnering
Our Pipeline
R&D Pipeline
In-house Programs
Partnered Programs
Our Medicines
Ultibro® and Seebri®
Enerzair® Breezhaler®
ORAVI®
PIVLAZ®
Newsroom
Press releases
In the News
Publications
Investors
Financial & IR Information
Presentations and Webcasts
Financial Results
Securities Reports
Annual Report
Financial Highlights
Analyst Coverage
Analyst Report
Stock Information
General Stock Information
Shareholder's Meetings & Publications
Corporate Governance
ESG Report 2022
Corporate Governance Report
Corporate Governance Guidelines
Modern Slavery Statements
Other IR Information
IR Blog (Japanese Only)
Events
Email Alerts
Careers
Careers
Global jobs portal
What's it like to work here
Join our Talent Community
Search
Careers
Contact
In the News
Press releases
In the News
Publications
LATEST
2021
Dec 7, 2022
Scrip
Sosei Heptares Eyes Asia Build-Out On Internal, External Assets
View Article
Aug 16, 2022
Business Weekly
No retreat, no surrender: Sosei Heptares takes hit to accelerate pipeline
View Article
Aug 2, 2022
Endpoints News
With some neuro targets in mind, AbbVie gets Sosei's drug discovery engine churning again
View Article
Jul 22, 2022
Endpoints News
Sosei Heptares partners with a UK-based cancer research organization to bring its drug to trial
View Article
Jan 6, 2022
Fierce Biotech
Verily links up with Sosei Heptares for GPCR drug discovery
View Article
Jan 6, 2022
PharmaTimes
Sosei Heptares and Verily to collaborate on immune-mediated disease treatments
View Article
Jan 6, 2022
Endpoints News
Sosei and Verily partner on GPCRs; ObsEva touts PhIII data in endometriosis pain - by Paul Schloesser
View Article
Nov 22, 2021
Fierce Biotech
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - Biotech Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - by Ben Adams
View Article
Nov 22, 2021
Endpoints News
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal - by John Carroll
View Article
Nov 22, 2021
BioCentury
Sosei finds second partner for muscarinic neurology assets in Neurocrine - by Stephen Hansen
Download PDF
Nov 22, 2021
BioWorld
Sosei, Neurocrine ink $2.6B neuropsychiatric collaboration - by Nuala Moran
Download PDF
LATEST
2021